Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 23 entries
Sorted by: Best Match Show Resources per page
[No title available]

Oncology letters

Bondavalli D, Malvestiti F, Pensotti V, Feroce I, Bonanni B.
PMID: 29435075
Oncol Lett. 2018 Mar;15(3):3329-3332. doi: 10.3892/ol.2017.7711. Epub 2017 Dec 28.

The present case report discusses a woman affected by chronic lymphatic leukemia and breast cancer with a familial history of breast cancer; suspected to be hereditary breast and ovarian cancer (HBOC) syndrome. The patient underwent

Cite
Bondavalli D, Malvestiti F, Pensotti V, et al. . Oncol Lett. 2017;15(3):3329-3332doi: 10.3892/ol.2017.7711.
Bondavalli, D., Malvestiti, F., Pensotti, V., Feroce, I., & Bonanni, B. (2018). . Oncology letters, 15(3), 3329-3332. https://doi.org/10.3892/ol.2017.7711
Bondavalli, Davide, et al. "." Oncology letters vol. 15,3 (2018): 3329-3332. doi: https://doi.org/10.3892/ol.2017.7711
Bondavalli D, Malvestiti F, Pensotti V, Feroce I, Bonanni B. . Oncol Lett. 2018 Mar;15(3):3329-3332. doi: 10.3892/ol.2017.7711. Epub 2017 Dec 28. PMID: 29435075; PMCID: PMC5778837.
Copy Download .nbib Format: NLM
Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation.

Blood cancer discovery

Gulla A, Morelli E, Samur MK, Botta C, Hideshima T, Bianchi G, Fulciniti M, Malvestiti S, Prabhala RH, Talluri S, Wen K, Tai YT, Richardson PG, Chauhan D, Sewastianik T, Carrasco RD, Munshi NC, Anderson KC.
PMID: 34568832
Blood Cancer Discov. 2021 Sep;2(5):468-483. doi: 10.1158/2643-3230.bcd-21-0047. Epub 2021 Apr 23.

Proteasome inhibitor bortezomib induces apoptosis in multiple myeloma (MM) cells, and has transformed patient outcome. Using

Cite
Gulla A, Morelli E, Samur MK, et al. Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. Blood Cancer Discov. 2021;2(5):468-483doi: 10.1158/2643-3230.bcd-21-0047.
Gulla, A., Morelli, E., Samur, M. K., Botta, C., Hideshima, T., Bianchi, G., Fulciniti, M., Malvestiti, S., Prabhala, R. H., Talluri, S., Wen, K., Tai, Y. T., Richardson, P. G., Chauhan, D., Sewastianik, T., Carrasco, R. D., Munshi, N. C., & Anderson, K. C. (2021). Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. Blood cancer discovery, 2(5), 468-483. https://doi.org/10.1158/2643-3230.bcd-21-0047
Gulla, Annamaria, et al. "Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation." Blood cancer discovery vol. 2,5 (2021): 468-483. doi: https://doi.org/10.1158/2643-3230.bcd-21-0047
Gulla A, Morelli E, Samur MK, Botta C, Hideshima T, Bianchi G, Fulciniti M, Malvestiti S, Prabhala RH, Talluri S, Wen K, Tai YT, Richardson PG, Chauhan D, Sewastianik T, Carrasco RD, Munshi NC, Anderson KC. Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. Blood Cancer Discov. 2021 Sep;2(5):468-483. doi: 10.1158/2643-3230.bcd-21-0047. Epub 2021 Apr 23. PMID: 34568832; PMCID: PMC8462183.
Copy Download .nbib Format: NLM
Integration of ozone, UV/H.

The Science of the total environment

Granzoto MR, Seabra I, Malvestiti JA, Cristale J, Dantas RF.
PMID: 33218803
Sci Total Environ. 2021 Mar 10;759:143498. doi: 10.1016/j.scitotenv.2020.143498. Epub 2020 Nov 11.

Current studies tend to combine different advanced treatment technologies to reduce costs and increase efficiency. The objective of this work was to assess the combination of ozonation and UV/H

Cite
Granzoto MR, Seabra I, Malvestiti JA, et al. Integration of ozone, UV/H. Sci Total Environ. 2020;759:143498doi: 10.1016/j.scitotenv.2020.143498.
Granzoto, M. R., Seabra, I., Malvestiti, J. A., Cristale, J., & Dantas, R. F. (2021). Integration of ozone, UV/H. The Science of the total environment, 759143498. https://doi.org/10.1016/j.scitotenv.2020.143498
Granzoto, Mariana R, et al. "Integration of ozone, UV/H." The Science of the total environment vol. 759 (2021): 143498. doi: https://doi.org/10.1016/j.scitotenv.2020.143498
Granzoto MR, Seabra I, Malvestiti JA, Cristale J, Dantas RF. Integration of ozone, UV/H. Sci Total Environ. 2021 Mar 10;759:143498. doi: 10.1016/j.scitotenv.2020.143498. Epub 2020 Nov 11. PMID: 33218803.
Copy Download .nbib Format: NLM
JunB is a key regulator of multiple myeloma bone marrow angiogenesis.

Leukemia

Fan F, Malvestiti S, Vallet S, Lind J, Garcia-Manteiga JM, Morelli E, Jiang Q, Seckinger A, Hose D, Goldschmidt H, Stadlbauer A, Sun C, Mei H, Pecherstorfer M, Bakiri L, Wagner EF, Tonon G, Sattler M, Hu Y, Tassone P, Jaeger D, Podar K.
PMID: 34007044
Leukemia. 2021 Dec;35(12):3509-3525. doi: 10.1038/s41375-021-01271-9. Epub 2021 May 18.

Bone marrow (BM) angiogenesis significantly influences disease progression in multiple myeloma (MM) patients and correlates with adverse prognosis. The present study shows a statistically significant correlation of the AP-1 family member JunB with VEGF, VEGFB, and IGF1 expression levels...

Cite
Fan F, Malvestiti S, Vallet S, et al. JunB is a key regulator of multiple myeloma bone marrow angiogenesis. Leukemia. 2021;35(12):3509-3525doi: 10.1038/s41375-021-01271-9.
Fan, F., Malvestiti, S., Vallet, S., Lind, J., Garcia-Manteiga, J. M., Morelli, E., Jiang, Q., Seckinger, A., Hose, D., Goldschmidt, H., Stadlbauer, A., Sun, C., Mei, H., Pecherstorfer, M., Bakiri, L., Wagner, E. F., Tonon, G., Sattler, M., Hu, Y., Tassone, P., Jaeger, D., & Podar, K. (2021). JunB is a key regulator of multiple myeloma bone marrow angiogenesis. Leukemia, 35(12), 3509-3525. https://doi.org/10.1038/s41375-021-01271-9
Fan, Fengjuan, et al. "JunB is a key regulator of multiple myeloma bone marrow angiogenesis." Leukemia vol. 35,12 (2021): 3509-3525. doi: https://doi.org/10.1038/s41375-021-01271-9
Fan F, Malvestiti S, Vallet S, Lind J, Garcia-Manteiga JM, Morelli E, Jiang Q, Seckinger A, Hose D, Goldschmidt H, Stadlbauer A, Sun C, Mei H, Pecherstorfer M, Bakiri L, Wagner EF, Tonon G, Sattler M, Hu Y, Tassone P, Jaeger D, Podar K. JunB is a key regulator of multiple myeloma bone marrow angiogenesis. Leukemia. 2021 Dec;35(12):3509-3525. doi: 10.1038/s41375-021-01271-9. Epub 2021 May 18. PMID: 34007044; PMCID: PMC8632680.
Copy Download .nbib Format: NLM
Definition of Healthy Ranges for Alanine Aminotransferase Levels: A 2021 Update.

Hepatology communications

Valenti L, Pelusi S, Bianco C, Ceriotti F, Berzuini A, Iogna Prat L, Trotti R, Malvestiti F, D'Ambrosio R, Lampertico P, Colli A, Colombo M, Tsochatzis EA, Fraquelli M, Prati D.
PMID: 34520121
Hepatol Commun. 2021 Nov;5(11):1824-1832. doi: 10.1002/hep4.1794. Epub 2021 Sep 14.

The changing epidemiology of liver disease, and modifications in the recommended analytical methodology call for a re-evaluation of the upper reference limits (URLs) of alanine aminotransferase (ALT) levels. Using the same approach consolidated 20 years ago to define the...

Cite
Valenti L, Pelusi S, Bianco C, et al. Definition of Healthy Ranges for Alanine Aminotransferase Levels: A 2021 Update. Hepatol Commun. 2021;5(11):1824-1832doi: 10.1002/hep4.1794.
Valenti, L., Pelusi, S., Bianco, C., Ceriotti, F., Berzuini, A., Iogna Prat, L., Trotti, R., Malvestiti, F., D'Ambrosio, R., Lampertico, P., Colli, A., Colombo, M., Tsochatzis, E. A., Fraquelli, M., & Prati, D. (2021). Definition of Healthy Ranges for Alanine Aminotransferase Levels: A 2021 Update. Hepatology communications, 5(11), 1824-1832. https://doi.org/10.1002/hep4.1794
Valenti, Luca, et al. "Definition of Healthy Ranges for Alanine Aminotransferase Levels: A 2021 Update." Hepatology communications vol. 5,11 (2021): 1824-1832. doi: https://doi.org/10.1002/hep4.1794
Valenti L, Pelusi S, Bianco C, Ceriotti F, Berzuini A, Iogna Prat L, Trotti R, Malvestiti F, D'Ambrosio R, Lampertico P, Colli A, Colombo M, Tsochatzis EA, Fraquelli M, Prati D. Definition of Healthy Ranges for Alanine Aminotransferase Levels: A 2021 Update. Hepatol Commun. 2021 Nov;5(11):1824-1832. doi: 10.1002/hep4.1794. Epub 2021 Sep 14. PMID: 34520121; PMCID: PMC8557310.
Copy Download .nbib Format: NLM
Performance of conventional cytogenetic analysis on chorionic villi when only one cell layer, cytotrophoblast or mesenchyme alone, is analyzed.

Prenatal diagnosis

Grati FR, Malvestiti F, Gallazzi G, Saragozza S, Grimi B, Agrati C, Branca L, Palumbo F, Trotta A, Chinetti S, Simoni G, Ferreira J, Benn P.
PMID: 33782989
Prenat Diagn. 2021 May;41(6):652-660. doi: 10.1002/pd.5941. Epub 2021 Apr 10.

OBJECTIVE: To provide an estimation of the probability of error when chorionic villi (CV) cytogenetic analysis is limited to a single placental layer; either a direct preparation (Dir) or long-term culture (LTC).METHODS: We retrospectively reviewed cytogenetic studies on 81,593...

Cite
Grati FR, Malvestiti F, Gallazzi G, et al. Performance of conventional cytogenetic analysis on chorionic villi when only one cell layer, cytotrophoblast or mesenchyme alone, is analyzed. Prenat Diagn. 2021;41(6):652-660doi: 10.1002/pd.5941.
Grati, F. R., Malvestiti, F., Gallazzi, G., Saragozza, S., Grimi, B., Agrati, C., Branca, L., Palumbo, F., Trotta, A., Chinetti, S., Simoni, G., Ferreira, J., & Benn, P. (2021). Performance of conventional cytogenetic analysis on chorionic villi when only one cell layer, cytotrophoblast or mesenchyme alone, is analyzed. Prenatal diagnosis, 41(6), 652-660. https://doi.org/10.1002/pd.5941
Grati, Francesca Romana, et al. "Performance of conventional cytogenetic analysis on chorionic villi when only one cell layer, cytotrophoblast or mesenchyme alone, is analyzed." Prenatal diagnosis vol. 41,6 (2021): 652-660. doi: https://doi.org/10.1002/pd.5941
Grati FR, Malvestiti F, Gallazzi G, Saragozza S, Grimi B, Agrati C, Branca L, Palumbo F, Trotta A, Chinetti S, Simoni G, Ferreira J, Benn P. Performance of conventional cytogenetic analysis on chorionic villi when only one cell layer, cytotrophoblast or mesenchyme alone, is analyzed. Prenat Diagn. 2021 May;41(6):652-660. doi: 10.1002/pd.5941. Epub 2021 Apr 10. PMID: 33782989.
Copy Download .nbib Format: NLM
Fire Blight Susceptibility in .

Frontiers in plant science

Malvestiti MC, Immink RGH, Arens P, Quiroz Monnens T, van Kan JAL.
PMID: 34262577
Front Plant Sci. 2021 Jun 28;12:660337. doi: 10.3389/fpls.2021.660337. eCollection 2021.

Fire blight represents a widespread disease in

Cite
Malvestiti MC, Immink RGH, Arens P, et al. Fire Blight Susceptibility in . Front Plant Sci. 2021;12:660337doi: 10.3389/fpls.2021.660337.
Malvestiti, M. C., Immink, R. G. H., Arens, P., Quiroz Monnens, T., & van Kan, J. A. L. (2021). Fire Blight Susceptibility in . Frontiers in plant science, 12660337. https://doi.org/10.3389/fpls.2021.660337
Malvestiti, Michele C, et al. "Fire Blight Susceptibility in ." Frontiers in plant science vol. 12 (2021): 660337. doi: https://doi.org/10.3389/fpls.2021.660337
Malvestiti MC, Immink RGH, Arens P, Quiroz Monnens T, van Kan JAL. Fire Blight Susceptibility in . Front Plant Sci. 2021 Jun 28;12:660337. doi: 10.3389/fpls.2021.660337. eCollection 2021. PMID: 34262577; PMCID: PMC8273286.
Copy Download .nbib Format: NLM
Corrigendum to "Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19" [J. Autoimmun. 117C (2020) 102595].

Journal of autoimmunity

Valenti L, Griffini S, Lamorte G, Grovetti E, Uceda Renteria SC, Malvestiti F, Scudeller L, Bandera A, Peyvandi F, Prati D, Meroni P, Cugno M.
PMID: 33940483
J Autoimmun. 2021 Jun;120:102646. doi: 10.1016/j.jaut.2021.102646. Epub 2021 Apr 30.

No abstract available.

Cite
Valenti L, Griffini S, Lamorte G, et al. Corrigendum to "Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19" [J. Autoimmun. 117C (2020) 102595]. J Autoimmun. 2021;120:102646doi: 10.1016/j.jaut.2021.102646.
Valenti, L., Griffini, S., Lamorte, G., Grovetti, E., Uceda Renteria, S. C., Malvestiti, F., Scudeller, L., Bandera, A., Peyvandi, F., Prati, D., Meroni, P., & Cugno, M. (2021). Corrigendum to "Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19" [J. Autoimmun. 117C (2020) 102595]. Journal of autoimmunity, 120102646. https://doi.org/10.1016/j.jaut.2021.102646
Valenti, Luca, et al. "Corrigendum to "Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19" [J. Autoimmun. 117C (2020) 102595]." Journal of autoimmunity vol. 120 (2021): 102646. doi: https://doi.org/10.1016/j.jaut.2021.102646
Valenti L, Griffini S, Lamorte G, Grovetti E, Uceda Renteria SC, Malvestiti F, Scudeller L, Bandera A, Peyvandi F, Prati D, Meroni P, Cugno M. Corrigendum to "Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19" [J. Autoimmun. 117C (2020) 102595]. J Autoimmun. 2021 Jun;120:102646. doi: 10.1016/j.jaut.2021.102646. Epub 2021 Apr 30. PMID: 33940483; PMCID: PMC8086412.
Copy Download .nbib Format: NLM
Mechanochemical Thiocyanation of Aryl Compounds .

ACS omega

de Oliveira Lima Filho E, Malvestiti I.
PMID: 33403295
ACS Omega. 2020 Dec 14;5(51):33329-33339. doi: 10.1021/acsomega.0c05131. eCollection 2020 Dec 29.

Aryl thiocyanate compounds are important building blocks for the synthesis of bioactive compounds and intermediates for several functional groups. Reported thiocyanation reactions

Cite
de Oliveira Lima Filho E, Malvestiti I. Mechanochemical Thiocyanation of Aryl Compounds . ACS Omega. 2020;5(51):33329-33339doi: 10.1021/acsomega.0c05131.
de Oliveira Lima Filho, E., & Malvestiti, I. (2020). Mechanochemical Thiocyanation of Aryl Compounds . ACS omega, 5(51), 33329-33339. https://doi.org/10.1021/acsomega.0c05131
de Oliveira Lima Filho, Edson, and Malvestiti, Ivani. "Mechanochemical Thiocyanation of Aryl Compounds ." ACS omega vol. 5,51 (2020): 33329-33339. doi: https://doi.org/10.1021/acsomega.0c05131
de Oliveira Lima Filho E, Malvestiti I. Mechanochemical Thiocyanation of Aryl Compounds . ACS Omega. 2020 Dec 14;5(51):33329-33339. doi: 10.1021/acsomega.0c05131. eCollection 2020 Dec 29. PMID: 33403295; PMCID: PMC7774286.
Copy Download .nbib Format: NLM
Trends and risk factors of SARS-CoV-2 infection in asymptomatic blood donors.

Transfusion

Valenti L, Pelusi S, Cherubini A, Bianco C, Ronzoni L, Uceda Renteria S, Coluccio E, Berzuini A, Lombardi A, Terranova L, Malvestiti F, Lamorte G, Erba E, Oggioni M, Ceriotti F, Prati D.
PMID: 34647620
Transfusion. 2021 Dec;61(12):3381-3389. doi: 10.1111/trf.16693. Epub 2021 Oct 14.

BACKGROUND: A large proportion of SARS-CoV-2-infected individuals does not develop severe symptoms. Serological tests help in evaluating the spread of infection and disease immunization. The aim of this study was to prospectively examine the trends and risk factors of...

Cite
Valenti L, Pelusi S, Cherubini A, et al. Trends and risk factors of SARS-CoV-2 infection in asymptomatic blood donors. Transfusion. 2021;61(12):3381-3389doi: 10.1111/trf.16693.
Valenti, L., Pelusi, S., Cherubini, A., Bianco, C., Ronzoni, L., Uceda Renteria, S., Coluccio, E., Berzuini, A., Lombardi, A., Terranova, L., Malvestiti, F., Lamorte, G., Erba, E., Oggioni, M., Ceriotti, F., & Prati, D. (2021). Trends and risk factors of SARS-CoV-2 infection in asymptomatic blood donors. Transfusion, 61(12), 3381-3389. https://doi.org/10.1111/trf.16693
Valenti, Luca, et al. "Trends and risk factors of SARS-CoV-2 infection in asymptomatic blood donors." Transfusion vol. 61,12 (2021): 3381-3389. doi: https://doi.org/10.1111/trf.16693
Valenti L, Pelusi S, Cherubini A, Bianco C, Ronzoni L, Uceda Renteria S, Coluccio E, Berzuini A, Lombardi A, Terranova L, Malvestiti F, Lamorte G, Erba E, Oggioni M, Ceriotti F, Prati D. Trends and risk factors of SARS-CoV-2 infection in asymptomatic blood donors. Transfusion. 2021 Dec;61(12):3381-3389. doi: 10.1111/trf.16693. Epub 2021 Oct 14. PMID: 34647620; PMCID: PMC8661834.
Copy Download .nbib Format: NLM
Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation.

Blood cancer discovery

Gulla A, Morelli E, Samur MK, Botta C, Hideshima T, Bianchi G, Fulciniti M, Malvestiti S, Prabhala RH, Talluri S, Wen K, Tai YT, Richardson PG, Chauhan D, Sewastianik T, Carrasco RD, Munshi NC, Anderson KC.
PMID: 34568832
Blood Cancer Discov. 2021 Sep;2(5):468-483. doi: 10.1158/2643-3230.BCD-21-0047. Epub 2021 Apr 23.

Proteasome inhibitor bortezomib induces apoptosis in multiple myeloma (MM) cells, and has transformed patient outcome. Using

Cite
Gulla A, Morelli E, Samur MK, et al. Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. Blood Cancer Discov. 2021;2(5):468-483doi: 10.1158/2643-3230.BCD-21-0047.
Gulla, A., Morelli, E., Samur, M. K., Botta, C., Hideshima, T., Bianchi, G., Fulciniti, M., Malvestiti, S., Prabhala, R. H., Talluri, S., Wen, K., Tai, Y. T., Richardson, P. G., Chauhan, D., Sewastianik, T., Carrasco, R. D., Munshi, N. C., & Anderson, K. C. (2021). Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. Blood cancer discovery, 2(5), 468-483. https://doi.org/10.1158/2643-3230.BCD-21-0047
Gulla, Annamaria, et al. "Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation." Blood cancer discovery vol. 2,5 (2021): 468-483. doi: https://doi.org/10.1158/2643-3230.BCD-21-0047
Gulla A, Morelli E, Samur MK, Botta C, Hideshima T, Bianchi G, Fulciniti M, Malvestiti S, Prabhala RH, Talluri S, Wen K, Tai YT, Richardson PG, Chauhan D, Sewastianik T, Carrasco RD, Munshi NC, Anderson KC. Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. Blood Cancer Discov. 2021 Sep;2(5):468-483. doi: 10.1158/2643-3230.BCD-21-0047. Epub 2021 Apr 23. PMID: 34568832; PMCID: PMC8462183.
Copy Download .nbib Format: NLM
Recombinant chromosome 4 from a familial pericentric inversion: prenatal and adulthood wolf-hirschhorn phenotypes.

Case reports in genetics

Malvestiti F, Benedicenti F, De Toffol S, Chinetti S, Höller A, Grimi B, Fichtel G, Braghetto M, Agrati C, Bonaparte E, Maggi F, Simoni G, Grati FR.
PMID: 23762669
Case Rep Genet. 2013;2013:306098. doi: 10.1155/2013/306098. Epub 2013 May 16.

Pericentric inversion of chromosome 4 can give rise to recombinant chromosomes by duplication or deletion of 4p. We report on a familial case of Wolf-Hirschhorn Syndrome characterized by GTG-banding karyotypes, FISH, and array CGH analysis, caused by a recombinant...

Cite
Malvestiti F, Benedicenti F, De Toffol S, et al. Recombinant chromosome 4 from a familial pericentric inversion: prenatal and adulthood wolf-hirschhorn phenotypes. Case Rep Genet. 2013;2013:306098doi: 10.1155/2013/306098.
Malvestiti, F., Benedicenti, F., De Toffol, S., Chinetti, S., Höller, A., Grimi, B., Fichtel, G., Braghetto, M., Agrati, C., Bonaparte, E., Maggi, F., Simoni, G., & Grati, F. R. (2013). Recombinant chromosome 4 from a familial pericentric inversion: prenatal and adulthood wolf-hirschhorn phenotypes. Case reports in genetics, 2013306098. https://doi.org/10.1155/2013/306098
Malvestiti, Francesca, et al. "Recombinant chromosome 4 from a familial pericentric inversion: prenatal and adulthood wolf-hirschhorn phenotypes." Case reports in genetics vol. 2013 (2013): 306098. doi: https://doi.org/10.1155/2013/306098
Malvestiti F, Benedicenti F, De Toffol S, Chinetti S, Höller A, Grimi B, Fichtel G, Braghetto M, Agrati C, Bonaparte E, Maggi F, Simoni G, Grati FR. Recombinant chromosome 4 from a familial pericentric inversion: prenatal and adulthood wolf-hirschhorn phenotypes. Case Rep Genet. 2013;2013:306098. doi: 10.1155/2013/306098. Epub 2013 May 16. PMID: 23762669; PMCID: PMC3670532.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 23 entries